{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T13:45:04Z","timestamp":1789911904894,"version":"4.0.1"},"reference-count":105,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T00:00:00Z","timestamp":1759795200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T00:00:00Z","timestamp":1759795200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Heart Fail Rev"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Chronic obstructive pulmonary disease (COPD) and heart failure (HF) frequently coexist and interact through complex and bidirectional hemodynamic mechanisms that amplify symptoms\u2019 burden and complicate clinical management. The present review explores the impact of COPD across the HF spectrum, particularly in HF with preserved ejection fraction (HFpEF), where comorbidities, such as COPD, exert a dominant role in disease expression. COPD-induced hyperinflation reduces cardiac preload and increases right ventricular afterload, while HF-related congestion impairs pulmonary function and gas exchange, illustrating a tight cardiorespiratory coupling. Diagnostic challenges stem from overlapping symptoms and the limited specificity of biomarkers, such as natriuretic peptides, especially in HFpEF. Cardiopulmonary exercise testing (CPET) emerges as a valuable tool for distinguishing between cardiac and pulmonary limitations and guiding individualized treatment strategies. From a therapeutic standpoint,\n                    <jats:italic>\u03b2<\/jats:italic>\n                    1-selective blockers are not only safe in COPD patients but are pivotal in those with HF with reduced ejection fraction (HFrEF), where they have been demonstrated to improve survival and reduce both HF and COPD exacerbations. Concerns regarding bronchodilator safety in HF remain largely theoretical, with current evidence supporting their continued use when clinically indicated. Ultimately, optimal care for patients with coexisting COPD and HF requires a phenotype-specific approach, incorporating insights from pathophysiology, diagnostic innovation, and evidence-based pharmacotherapy to improve outcomes in this challenging patient population.\n                  <\/jats:p>","DOI":"10.1007\/s10741-025-10566-3","type":"journal-article","created":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T22:27:37Z","timestamp":1759789657000},"page":"1525-1538","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Heart failure and chronic obstructive pulmonary disease. A combination not to be underestimated"],"prefix":"10.1007","volume":"30","author":[{"given":"Damiano","family":"Magr\u00ec","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8749-8558","authenticated-orcid":false,"given":"Emiliano","family":"Fiori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piergiuseppe","family":"Agostoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Correale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Piepoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Savina","family":"Nodari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Beltrami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Paolillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pasquale Perrone","family":"Filardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Palazzuoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the Working Group on Heart Failure of the Italian Society of Cardiology","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,7]]},"reference":[{"issue":"12","key":"10566_CR1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.46598","volume":"6","author":"E Boers","year":"2023","unstructured":"Boers E, Barrett M, Su JG et al (2023) Global burden of chronic obstructive pulmonary disease through 2050. JAMA Netw Open 6(12):e2346598. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.46598","journal-title":"JAMA Netw Open"},{"issue":"17","key":"10566_CR2","doi-asserted-by":"publisher","first-page":"3272","DOI":"10.1093\/cvr\/cvac013","volume":"118","author":"G Savarese","year":"2023","unstructured":"Savarese G, Becher PM, Lund LH, Seferovic P, Rosano GMC, Coats AJS (2023) Global burden of heart failure: a comprehensive and updated review of epidemiology. Cardiovasc Res 118(17):3272\u20133287. https:\/\/doi.org\/10.1093\/cvr\/cvac013","journal-title":"Cardiovasc Res"},{"issue":"7","key":"10566_CR3","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1002\/ejhf.3646","volume":"27","author":"GMC Rosano","year":"2025","unstructured":"Rosano GMC, Teerlink JR, Kinugawa K et al (2025) The use of left ventricular ejection fraction in the diagnosis and management of heart failure. A clinical consensus statement of the Heart Failure Association (HFA) of the ESC, the Heart Failure Society of America (HFSA), and the Japanese Heart Failure Society (JHFS). Eur J Heart Fail 27(7):1174\u20131187. https:\/\/doi.org\/10.1002\/ejhf.3646","journal-title":"Eur J Heart Fail"},{"key":"10566_CR4","doi-asserted-by":"publisher","unstructured":"Basile C, Maggioni AP (2025) Heart failure in an ageing world: closing the evidence-equity gap. Eur Heart J Qual Care Clin Outcomes: qcaf046. https:\/\/doi.org\/10.1093\/ehjqcco\/qcaf046. (Published online June 25)","DOI":"10.1093\/ehjqcco\/qcaf046"},{"issue":"10","key":"10566_CR5","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1016\/j.jcmg.2021.03.026","volume":"14","author":"J Lagan","year":"2021","unstructured":"Lagan J, Schelbert EB, Naish JH et al (2021) Mechanisms underlying the association of chronic obstructive pulmonary disease with heart failure. JACC Cardiovasc Imaging 14(10):1963\u20131973. https:\/\/doi.org\/10.1016\/j.jcmg.2021.03.026","journal-title":"JACC Cardiovasc Imaging"},{"issue":"8","key":"10566_CR6","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1513\/AnnalsATS.201911-820OC","volume":"17","author":"EL Axson","year":"2020","unstructured":"Axson EL, Sundaram V, Bloom CI, Bottle A, Cowie MR, Quint JK (2020) Temporal trends in the incidence of heart failure among patients with chronic obstructive pulmonary disease and its association with mortality. Ann ATS 17(8):939\u2013948. https:\/\/doi.org\/10.1513\/AnnalsATS.201911-820OC","journal-title":"Ann ATS"},{"issue":"1","key":"10566_CR7","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1186\/s12890-023-02606-1","volume":"23","author":"H Chen","year":"2023","unstructured":"Chen H, Luo X, Du Y et al (2023) Association between chronic obstructive pulmonary disease and cardiovascular disease in adults aged 40 years and above: data from NHANES 2013\u20132018. BMC Pulm Med 23(1):318. https:\/\/doi.org\/10.1186\/s12890-023-02606-1","journal-title":"BMC Pulm Med"},{"issue":"6","key":"10566_CR8","doi-asserted-by":"publisher","first-page":"00548","DOI":"10.1183\/23120541.00548-2023","volume":"9","author":"J Kibbler","year":"2023","unstructured":"Kibbler J, Wade C, Mussell G, Ripley DP, Bourke SC, Steer J (2023) Systematic review and meta-analysis of prevalence of undiagnosed major cardiac comorbidities in COPD. ERJ Open Res 9(6):00548\u201302023. https:\/\/doi.org\/10.1183\/23120541.00548-2023","journal-title":"ERJ Open Res"},{"issue":"6","key":"10566_CR9","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1513\/AnnalsATS.202107-823OC","volume":"19","author":"C Gulea","year":"2022","unstructured":"Gulea C, Zakeri R, Quint JK (2022) Differences in outcomes between heart failure phenotypes in patients with coexistent chronic obstructive pulmonary disease: a cohort study. Ann Am Thorac Soc 19(6):971\u2013980. https:\/\/doi.org\/10.1513\/AnnalsATS.202107-823OC","journal-title":"Ann Am Thorac Soc"},{"issue":"1","key":"10566_CR10","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s12931-020-1312-7","volume":"21","author":"EL Axson","year":"2020","unstructured":"Axson EL, Ragutheeswaran K, Sundaram V et al (2020) Hospitalisation and mortality in patients with comorbid COPD and heart failure: a systematic review and meta-analysis. Respir Res 21(1):54. https:\/\/doi.org\/10.1186\/s12931-020-1312-7","journal-title":"Respir Res"},{"issue":"9","key":"10566_CR11","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1002\/ejhf.2962","volume":"25","author":"M Yang","year":"2023","unstructured":"Yang M, Kondo T, Adamson C et al (2023) Impact of comorbidities on health status measured using the Kansas City cardiomyopathy questionnaire in patients with heart failure with reduced and preserved ejection fraction. Eur J Heart Fail 25(9):1606\u20131618. https:\/\/doi.org\/10.1002\/ejhf.2962","journal-title":"Eur J Heart Fail"},{"key":"10566_CR12","doi-asserted-by":"publisher","DOI":"10.1002\/ehf2.15127","author":"PM Becher","year":"2024","unstructured":"Becher PM, Lindberg F, Benson L et al (2024) Phenotyping patients with chronic obstructive pulmonary disease and heart failure. ESC Heart Fail. https:\/\/doi.org\/10.1002\/ehf2.15127. (Published online November 7, 2024)","journal-title":"ESC Heart Fail"},{"key":"10566_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2024.107536","volume":"223","author":"F Lau","year":"2024","unstructured":"Lau F, Schupp T, Schmitt A et al (2024) Prognostic impact of chronic obstructive pulmonary disease in patients with heart failure with mildly reduced ejection fraction. Respir Med 223:107536. https:\/\/doi.org\/10.1016\/j.rmed.2024.107536","journal-title":"Respir Med"},{"issue":"1","key":"10566_CR14","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1002\/ejhf.964","volume":"20","author":"M Canepa","year":"2018","unstructured":"Canepa M, Straburzynska-Migaj E, Drozdz J et al (2018) Characteristics, treatments and 1-year prognosis of hospitalized and ambulatory heart failure patients with chronic obstructive pulmonary disease in the European Society of Cardiology Heart Failure Long-Term Registry. Eur J Heart Fail 20(1):100\u2013110. https:\/\/doi.org\/10.1002\/ejhf.964","journal-title":"Eur J Heart Fail"},{"issue":"3","key":"10566_CR15","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1002\/ejhf.2350","volume":"24","author":"SE Yeoh","year":"2022","unstructured":"Yeoh SE, Dewan P, Serenelli M et al (2022) Effects of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction patients with chronic obstructive pulmonary disease in EMPHASIS-HF and RALES. Eur J Heart Fail 24(3):529\u2013538. https:\/\/doi.org\/10.1002\/ejhf.2350","journal-title":"Eur J Heart Fail"},{"issue":"4","key":"10566_CR16","doi-asserted-by":"publisher","first-page":"e019238","DOI":"10.1161\/JAHA.120.019238","volume":"10","author":"S Ehteshami-Afshar","year":"2021","unstructured":"Ehteshami-Afshar S, Mooney L, Dewan P et al (2021) Clinical characteristics and outcomes of patients with heart failure with reduced ejection fraction and chronic obstructive pulmonary disease: insights from PARADIGM-HF. J Am Heart Assoc 10(4):e019238. https:\/\/doi.org\/10.1161\/JAHA.120.019238","journal-title":"J Am Heart Assoc"},{"issue":"4","key":"10566_CR17","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1002\/ejhf.2083","volume":"23","author":"P Dewan","year":"2021","unstructured":"Dewan P, Docherty KF, Bengtsson O et al (2021) Effects of dapagliflozin in heart failure with reduced ejection fraction and chronic obstructive pulmonary disease: an analysis of DAPA-HF. Eur J Heart Fail 23(4):632\u2013643. https:\/\/doi.org\/10.1002\/ejhf.2083","journal-title":"Eur J Heart Fail"},{"issue":"3","key":"10566_CR18","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1002\/ejhf.1593","volume":"22","author":"SHR Ramalho","year":"2020","unstructured":"Ramalho SHR, Claggett BL, Sweitzer NK et al (2020) Impact of pulmonary disease on the prognosis in heart failure with preserved ejection fraction: the TOPCAT trial. Eur J Heart Fail 22(3):557\u2013559. https:\/\/doi.org\/10.1002\/ejhf.1593","journal-title":"Eur J Heart Fail"},{"issue":"23","key":"10566_CR19","doi-asserted-by":"publisher","first-page":"e021494","DOI":"10.1161\/JAHA.121.021494","volume":"10","author":"L Mooney","year":"2021","unstructured":"Mooney L, Hawkins NM, Jhund PS et al (2021) Impact of chronic obstructive pulmonary disease in patients with heart failure with preserved ejection fraction: insights from PARAGON-HF. J Am Heart Assoc 10(23):e021494. https:\/\/doi.org\/10.1161\/JAHA.121.021494","journal-title":"J Am Heart Assoc"},{"issue":"11","key":"10566_CR20","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1002\/ejhf.3000","volume":"25","author":"JH Butt","year":"2023","unstructured":"Butt JH, Lu H, Kondo T et al (2023) Heart failure, chronic obstructive pulmonary disease and efficacy and safety of dapagliflozin in heart failure with mildly reduced or preserved ejection fraction: insights from DELIVER. Eur J Heart Fail 25(11):2078\u20132090. https:\/\/doi.org\/10.1002\/ejhf.3000","journal-title":"Eur J Heart Fail"},{"issue":"Supplement_1","key":"10566_CR21","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehae666.1171","volume":"45","author":"S Von Haehling","year":"2024","unstructured":"Von Haehling S, Butler J, Anker SD (2024) Effectiveness of empagliflozin in patients with heart failure and COPD: results from emperor-preserved and emperor-reduced. Eur Heart J 45(Supplement_1):ehae666.1171. https:\/\/doi.org\/10.1093\/eurheartj\/ehae666.1171","journal-title":"Eur Heart J"},{"key":"10566_CR22","doi-asserted-by":"publisher","DOI":"10.1002\/ehf2.14958","author":"S Xu","year":"2024","unstructured":"Xu S, Gu Z, Zhu W, Feng S (2024) Association of COPD with adverse outcomes in heart failure patients with preserved ejection fraction. ESC Heart Fail. https:\/\/doi.org\/10.1002\/ehf2.14958. (Published online July 12, 2024)","journal-title":"ESC Heart Fail"},{"issue":"6","key":"10566_CR23","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1007\/s11897-016-0309-5","volume":"13","author":"S Caravita","year":"2016","unstructured":"Caravita S, Vachi\u00e9ry JL (2016) Obstructive ventilatory disorder in heart failure\u2014caused by the heart or the lung? Curr Heart Fail Rep 13(6):310\u2013318. https:\/\/doi.org\/10.1007\/s11897-016-0309-5","journal-title":"Curr Heart Fail Rep"},{"issue":"3","key":"10566_CR24","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1378\/chest.103.3.865","volume":"103","author":"RC Wetzel","year":"1993","unstructured":"Wetzel RC, Herold CJ, Zerhouni EA, Robotham JL (1993) Intravascular volume loading reversibly decreases airway cross-sectional area. Chest 103(3):865\u2013870. https:\/\/doi.org\/10.1378\/chest.103.3.865","journal-title":"Chest"},{"issue":"1","key":"10566_CR25","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1038\/s41598-022-05192-0","volume":"12","author":"A Orea-Tejeda","year":"2022","unstructured":"Orea-Tejeda A, G\u00f3mez-Mart\u00ednez M, Gonz\u00e1lez-Islas D et al (2022) The impact of hydration status and fluid distribution on pulmonary function in COPD patients. Sci Rep 12(1):1216. https:\/\/doi.org\/10.1038\/s41598-022-05192-0","journal-title":"Sci Rep"},{"issue":"21","key":"10566_CR26","doi-asserted-by":"publisher","first-page":"2538","DOI":"10.1093\/eurheartj\/ehl302","volume":"27","author":"P Agostoni","year":"2006","unstructured":"Agostoni P, Bussotti M, Cattadori G et al (2006) Gas diffusion and alveolar-capillary unit in chronic heart failure. Eur Heart J 27(21):2538\u20132543. https:\/\/doi.org\/10.1093\/eurheartj\/ehl302","journal-title":"Eur Heart J"},{"issue":"3","key":"10566_CR27","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1161\/CIRCHEARTFAILURE.108.819607","volume":"2","author":"D Magr\u00ec","year":"2009","unstructured":"Magr\u00ec D, Brioschi M, Banfi C et al (2009) Circulating plasma surfactant protein type B as biological marker of alveolar-capillary barrier damage in chronic heart failure. Circ Heart Fail 2(3):175\u2013180. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.108.819607","journal-title":"Circ Heart Fail"},{"key":"10566_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2024.132041","volume":"407","author":"B Pezzuto","year":"2024","unstructured":"Pezzuto B, Contini M, Berna G et al (2024) Dynamic trend of lung fluid movement during exercise in heart failure: from lung imaging to alveolar-capillary membrane function. Int J Cardiol 407:132041. https:\/\/doi.org\/10.1016\/j.ijcard.2024.132041","journal-title":"Int J Cardiol"},{"issue":"5","key":"10566_CR29","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.114.001678","volume":"4","author":"G Malfatto","year":"2015","unstructured":"Malfatto G, Caravita S, Giglio A et al (2015) Pulmonary congestion at rest and abnormal ventilation during exercise in chronic systolic heart failure. J Am Heart Assoc 4(5):e001678. https:\/\/doi.org\/10.1161\/JAHA.114.001678","journal-title":"J Am Heart Assoc"},{"key":"10566_CR30","doi-asserted-by":"publisher","unstructured":"Agostoni P, Cattadori G, Guazzi M, Palermo P, Bussotti M, Marenzi G (2000) Cardiomegaly as a possible cause of lung dysfunction in patients with heart failure. Am Heart J 140(5). https:\/\/doi.org\/10.1067\/mhj.2000.110282","DOI":"10.1067\/mhj.2000.110282"},{"issue":"17","key":"10566_CR31","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1016\/j.jacc.2019.01.072","volume":"73","author":"MG Del Buono","year":"2019","unstructured":"Del Buono MG, Arena R, Borlaug BA et al (2019) Exercise intolerance in patients with heart failure: JACC state-of-the-art review. J Am Coll Cardiol 73(17):2209\u20132225. https:\/\/doi.org\/10.1016\/j.jacc.2019.01.072","journal-title":"J Am Coll Cardiol"},{"key":"10566_CR32","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2023.1149065","volume":"10","author":"N Mangner","year":"2023","unstructured":"Mangner N, Winzer EB, Linke A, Adams V (2023) Locomotor and respiratory muscle abnormalities in HFrEF and HFpEF. Front Cardiovasc Med 10:1149065. https:\/\/doi.org\/10.3389\/fcvm.2023.1149065","journal-title":"Front Cardiovasc Med"},{"issue":"9","key":"10566_CR33","doi-asserted-by":"publisher","first-page":"1716","DOI":"10.1002\/ejhf.2980","volume":"25","author":"B Warner","year":"2023","unstructured":"Warner B, Bruhn EJ, Olson TP, Bissen TG, Borlaug BA, Smith JR (2023) Inspiratory muscle strength is related to exertional dyspnoea in heart failure with preserved ejection fraction. Eur J Heart Fail 25(9):1716\u20131717. https:\/\/doi.org\/10.1002\/ejhf.2980","journal-title":"Eur J Heart Fail"},{"issue":"4","key":"10566_CR34","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1183\/09031936.00222511","volume":"41","author":"X Freixa","year":"2013","unstructured":"Freixa X, Portillo K, Par\u00e9 C et al (2013) Echocardiographic abnormalities in patients with COPD at their first hospital admission. Eur Respir J 41(4):784\u2013791. https:\/\/doi.org\/10.1183\/09031936.00222511","journal-title":"Eur Respir J"},{"issue":"3","key":"10566_CR35","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1056\/NEJMoa0808836","volume":"362","author":"RG Barr","year":"2010","unstructured":"Barr RG, Bluemke DA, Ahmed FS et al (2010) Percent emphysema, airflow obstruction, and impaired left ventricular filling. N Engl J Med 362(3):217\u2013227. https:\/\/doi.org\/10.1056\/NEJMoa0808836","journal-title":"N Engl J Med"},{"issue":"4","key":"10566_CR36","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1378\/chest.13-0183","volume":"144","author":"BM Smith","year":"2013","unstructured":"Smith BM, Prince MR, Hoffman EA et al (2013) Impaired left ventricular filling in COPD and emphysema: is it the heart or the lungs? The multi-ethnic study of atherosclerosis COPD study. Chest 144(4):1143. https:\/\/doi.org\/10.1378\/chest.13-0183","journal-title":"Chest"},{"issue":"19","key":"10566_CR37","doi-asserted-by":"publisher","first-page":"2000","DOI":"10.1016\/j.jacc.2014.07.991","volume":"64","author":"SM Kawut","year":"2014","unstructured":"Kawut SM, Poor HD, Parikh MA et al (2014) Cor pulmonale parvus in chronic obstructive pulmonary disease and emphysema: the MESA COPD study. J Am Coll Cardiol 64(19):2000\u20132009. https:\/\/doi.org\/10.1016\/j.jacc.2014.07.991","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"10566_CR38","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1515\/jbcpp-2019-0311","volume":"32","author":"RV Cherneva","year":"2020","unstructured":"Cherneva RV, Denchev SV, Cherneva ZV (2020) The link between dynamic hyperinflation, autonomic dysfunction and exercise testing parameters with masked heart failure in patients with non-severe obstructive pulmonary disease. J Basic Clin Physiol Pharmacol 32(3):179\u2013188. https:\/\/doi.org\/10.1515\/jbcpp-2019-0311","journal-title":"J Basic Clin Physiol Pharmacol"},{"key":"10566_CR39","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.rmed.2018.02.011","volume":"137","author":"P Alter","year":"2018","unstructured":"Alter P, Watz H, Kahnert K et al (2018) Airway obstruction and lung hyperinflation in COPD are linked to an impaired left ventricular diastolic filling. Respir Med 137:14\u201322. https:\/\/doi.org\/10.1016\/j.rmed.2018.02.011","journal-title":"Respir Med"},{"issue":"17","key":"10566_CR40","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1016\/j.jacc.2022.08.760","volume":"80","author":"HM Salah","year":"2022","unstructured":"Salah HM, Goldberg LR, Molinger J et al (2022) Diaphragmatic function in cardiovascular disease: JACC review topic of the week. J Am Coll Cardiol 80(17):1647\u20131659. https:\/\/doi.org\/10.1016\/j.jacc.2022.08.760","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"10566_CR41","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1183\/09031936.00085612","volume":"41","author":"JM Hilde","year":"2013","unstructured":"Hilde JM, Skj\u00f8rten I, Hansteen V et al (2013) Haemodynamic responses to exercise in patients with COPD. Eur Respir J 41(5):1031\u20131041. https:\/\/doi.org\/10.1183\/09031936.00085612","journal-title":"Eur Respir J"},{"key":"10566_CR42","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.2147\/COPD.S78180","volume":"10","author":"K Portillo","year":"2015","unstructured":"Portillo K, Torralba Y, Blanco I et al (2015) Pulmonary hemodynamic profile in chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 10:1313\u20131320. https:\/\/doi.org\/10.2147\/COPD.S78180","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"1","key":"10566_CR43","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1186\/s12931-022-02238-9","volume":"23","author":"T Sassmann","year":"2022","unstructured":"Sassmann T, Douschan P, Foris V et al (2022) Abnormal pulmonary hemodynamics during exercise is associated with exercise capacity in COPD. Respir Res 23(1):331. https:\/\/doi.org\/10.1186\/s12931-022-02238-9","journal-title":"Respir Res"},{"issue":"3","key":"10566_CR44","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1152\/japplphysiol.00877.2018","volume":"127","author":"JR Smith","year":"2019","unstructured":"Smith JR, Johnson BD, Olson TP (2019) Impaired central hemodynamics in chronic obstructive pulmonary disease during submaximal exercise. J Appl Physiol 127(3):691\u2013697. https:\/\/doi.org\/10.1152\/japplphysiol.00877.2018","journal-title":"J Appl Physiol"},{"key":"10566_CR45","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.826369","volume":"9","author":"A Yogeswaran","year":"2022","unstructured":"Yogeswaran A, Kuhnert S, Gall H et al (2022) Relevance of cor pulmonale in COPD with and without pulmonary hypertension: a retrospective cohort study. Front Cardiovasc Med 9:826369. https:\/\/doi.org\/10.3389\/fcvm.2022.826369","journal-title":"Front Cardiovasc Med"},{"key":"10566_CR46","doi-asserted-by":"publisher","DOI":"10.1093\/eurjpc\/zwae348","author":"D Magr\u00ec","year":"2024","unstructured":"Magr\u00ec D, Piepoli M, Gallo G et al (2024) Chronotropic incompetence across heart failure categories. Eur J Prev Cardiol. https:\/\/doi.org\/10.1093\/eurjpc\/zwae348","journal-title":"Eur J Prev Cardiol"},{"issue":"3","key":"10566_CR47","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s11897-024-00660-2","volume":"21","author":"SHR Ramalho","year":"2024","unstructured":"Ramalho SHR, de Albuquerque ALP (2024) Chronic obstructive pulmonary disease in heart failure: challenges in diagnosis and treatment for HFpEF and HFrEF. Curr Heart Fail Rep 21(3):163\u2013173. https:\/\/doi.org\/10.1007\/s11897-024-00660-2","journal-title":"Curr Heart Fail Rep"},{"issue":"2","key":"10566_CR48","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1093\/eurjhf\/hfn013","volume":"11","author":"NM Hawkins","year":"2009","unstructured":"Hawkins NM, Petrie MC, Jhund PS, Chalmers GW, Dunn FG, McMurray JJV (2009) Heart failure and chronic obstructive pulmonary disease: diagnostic pitfalls and epidemiology. Eur J Heart Fail 11(2):130\u2013139. https:\/\/doi.org\/10.1093\/eurjhf\/hfn013","journal-title":"Eur J Heart Fail"},{"issue":"36","key":"10566_CR49","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","volume":"42","author":"TA McDonagh","year":"2021","unstructured":"McDonagh TA, Metra M, Adamo M et al (2021) 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 42(36):3599\u20133726. https:\/\/doi.org\/10.1093\/eurheartj\/ehab368","journal-title":"Eur Heart J"},{"issue":"4","key":"10566_CR50","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1002\/ehf2.12742","volume":"7","author":"P Garg","year":"2020","unstructured":"Garg P, Wood S, Swift AJ et al (2020) Clinical predictors of all-cause mortality in patients presenting to specialist heart failure clinic with raised NT-proBNP and no heart failure. ESC Heart Fail 7(4):1791\u20131800. https:\/\/doi.org\/10.1002\/ehf2.12742","journal-title":"ESC Heart Fail"},{"issue":"20","key":"10566_CR51","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1093\/eurheartj\/ehab911","volume":"43","author":"FH Verbrugge","year":"2022","unstructured":"Verbrugge FH, Omote K, Reddy YNV, Sorimachi H, Obokata M, Borlaug BA (2022) Heart failure with preserved ejection fraction in patients with normal natriuretic peptide levels is associated with increased morbidity and mortality. Eur Heart J 43(20):1941\u20131951. https:\/\/doi.org\/10.1093\/eurheartj\/ehab911","journal-title":"Eur Heart J"},{"issue":"1","key":"10566_CR52","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1186\/s12916-020-01764-x","volume":"18","author":"S Remmelzwaal","year":"2020","unstructured":"Remmelzwaal S, van Ballegooijen AJ, Schoonmade LJ et al (2020) Natriuretic peptides for the detection of diastolic dysfunction and heart failure with preserved ejection fraction\u2014a systematic review and meta-analysis. BMC Med 18(1):290. https:\/\/doi.org\/10.1186\/s12916-020-01764-x","journal-title":"BMC Med"},{"issue":"6\u20137","key":"10566_CR53","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/j.ejheart.2007.01.010","volume":"9","author":"FH Rutten","year":"2007","unstructured":"Rutten FH, Cramer MJM, Zuithoff NPA et al (2007) Comparison of B-type natriuretic peptide assays for identifying heart failure in stable elderly patients with a clinical diagnosis of chronic obstructive pulmonary disease. Eur J Heart Fail 9(6\u20137):651\u2013659. https:\/\/doi.org\/10.1016\/j.ejheart.2007.01.010","journal-title":"Eur J Heart Fail"},{"issue":"5","key":"10566_CR54","doi-asserted-by":"publisher","first-page":"3232","DOI":"10.1002\/ehf2.14894","volume":"11","author":"E Berthelot","year":"2024","unstructured":"Berthelot E, Bailly MT, Lehova XC et al (2024) Setting the optimal threshold of NT-proBNP and BNP for the diagnosis of heart failure in patients over 75 years. ESC Heart Fail 11(5):3232\u20133241. https:\/\/doi.org\/10.1002\/ehf2.14894","journal-title":"ESC Heart Fail"},{"key":"10566_CR55","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s12890-016-0345-7","volume":"17","author":"NM Hawkins","year":"2017","unstructured":"Hawkins NM, Khosla A, Virani SA, McMurray JJV, FitzGerald JM (2017) B-type natriuretic peptides in chronic obstructive pulmonary disease: a systematic review. BMC Pulm Med 17:11. https:\/\/doi.org\/10.1186\/s12890-016-0345-7","journal-title":"BMC Pulm Med"},{"issue":"6","key":"10566_CR56","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1007\/s00059-019-4814-7","volume":"44","author":"G G\u00fcder","year":"2019","unstructured":"G\u00fcder G, St\u00f6rk S (2019) COPD and heart failure: differential diagnosis and comorbidity. Herz 44(6):502\u2013508. https:\/\/doi.org\/10.1007\/s00059-019-4814-7","journal-title":"Herz"},{"issue":"10","key":"10566_CR57","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1016\/j.jchf.2019.05.009","volume":"7","author":"M Canepa","year":"2019","unstructured":"Canepa M, Franssen FME, Olschewski H et al (2019) Diagnostic and therapeutic gaps in patients with heart failure and chronic obstructive pulmonary disease. JACC: Heart Failure 7(10):823\u2013833. https:\/\/doi.org\/10.1016\/j.jchf.2019.05.009","journal-title":"JACC: Heart Failure"},{"issue":"8","key":"10566_CR58","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2018.5486","volume":"1","author":"FH Rutten","year":"2018","unstructured":"Rutten FH, Broekhuizen BDL (2018) Misclassification of both chronic obstructive pulmonary disease and heart failure. JAMA Netw Open 1(8):e185486. https:\/\/doi.org\/10.1001\/jamanetworkopen.2018.5486","journal-title":"JAMA Netw Open"},{"issue":"3","key":"10566_CR59","doi-asserted-by":"publisher","first-page":"1910","DOI":"10.1016\/j.ijcard.2012.12.083","volume":"168","author":"S Brenner","year":"2013","unstructured":"Brenner S, G\u00fcder G, Berliner D et al (2013) Airway obstruction in systolic heart failure \u2013 COPD or congestion? Int J Cardiol 168(3):1910\u20131916. https:\/\/doi.org\/10.1016\/j.ijcard.2012.12.083","journal-title":"Int J Cardiol"},{"issue":"14","key":"10566_CR60","doi-asserted-by":"publisher","first-page":"e023990","DOI":"10.1161\/JAHA.121.023990","volume":"11","author":"SHR Ramalho","year":"2022","unstructured":"Ramalho SHR, Claggett BL, Washko GR et al (2022) Association of pulmonary function with late-life cardiac function and heart failure risk: the ARIC study. J Am Heart Assoc 11(14):e023990. https:\/\/doi.org\/10.1161\/JAHA.121.023990","journal-title":"J Am Heart Assoc"},{"issue":"8","key":"10566_CR61","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/j.cardfail.2012.05.008","volume":"18","author":"G G\u00fcder","year":"2012","unstructured":"G\u00fcder G, Rutten FH, Brenner S et al (2012) The impact of heart failure on the classification of COPD severity. J Card Fail 18(8):637\u2013644. https:\/\/doi.org\/10.1016\/j.cardfail.2012.05.008","journal-title":"J Card Fail"},{"issue":"1","key":"10566_CR62","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0087395","volume":"9","author":"P Gargiulo","year":"2014","unstructured":"Gargiulo P, Apostolo A, Perrone-Filardi P, Sciomer S, Palange P, Agostoni P (2014) A non invasive estimate of dead space ventilation from exercise measurements. PLoS ONE 9(1):e87395. https:\/\/doi.org\/10.1371\/journal.pone.0087395","journal-title":"PLoS ONE"},{"key":"10566_CR63","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.ijcard.2015.03.422","volume":"189","author":"A Apostolo","year":"2015","unstructured":"Apostolo A, Laveneziana P, Palange P et al (2015) Impact of chronic obstructive pulmonary disease on exercise ventilatory efficiency in heart failure. Int J Cardiol 189:134\u2013140. https:\/\/doi.org\/10.1016\/j.ijcard.2015.03.422","journal-title":"Int J Cardiol"},{"key":"10566_CR64","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.ijcard.2018.09.007","volume":"274","author":"JR Smith","year":"2018","unstructured":"Smith JR, Iterson EHV, Johnson BD, Borlaug BA, Olson TP (2018) Exercise ventilatory inefficiency in heart failure and chronic obstructive pulmonary disease. Int J Cardiol 274:232. https:\/\/doi.org\/10.1016\/j.ijcard.2018.09.007","journal-title":"Int J Cardiol"},{"key":"10566_CR65","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2020.104785","volume":"156","author":"G Sinagra","year":"2020","unstructured":"Sinagra G, Corr\u00e0 U, Contini M et al (2020) Choosing among \u03b2-blockers in heart failure patients according to \u03b2-receptors\u2019 location and functions in the cardiopulmonary system. Pharmacol Res 156:104785. https:\/\/doi.org\/10.1016\/j.phrs.2020.104785","journal-title":"Pharmacol Res"},{"issue":"8","key":"10566_CR66","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1016\/j.ejheart.2007.04.006","volume":"9","author":"P Agostoni","year":"2007","unstructured":"Agostoni P, Contini M, Cattadori G et al (2007) Lung function with carvedilol and bisoprolol in chronic heart failure: is beta selectivity relevant? Eur J Heart Fail 9(8):827\u2013833. https:\/\/doi.org\/10.1016\/j.ejheart.2007.04.006","journal-title":"Eur J Heart Fail"},{"issue":"17","key":"10566_CR67","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.1016\/j.jacc.2010.01.024","volume":"55","author":"A Jabbour","year":"2010","unstructured":"Jabbour A, Macdonald PS, Keogh AM et al (2010) Differences between beta-blockers in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized crossover trial. J Am Coll Cardiol 55(17):1780\u20131787. https:\/\/doi.org\/10.1016\/j.jacc.2010.01.024","journal-title":"J Am Coll Cardiol"},{"issue":"Suppl 1","key":"10566_CR68","doi-asserted-by":"publisher","first-page":"S44","DOI":"10.1016\/S0954-6111(11)70010-5","volume":"105","author":"M Lainscak","year":"2011","unstructured":"Lainscak M, Podbregar M, Kovacic D, Rozman J, von Haehling S (2011) Differences between bisoprolol and carvedilol in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized trial. Respir Med 105(Suppl 1):S44-49. https:\/\/doi.org\/10.1016\/S0954-6111(11)70010-5","journal-title":"Respir Med"},{"issue":"3","key":"10566_CR69","doi-asserted-by":"publisher","first-page":"2134","DOI":"10.1016\/j.ijcard.2013.01.277","volume":"168","author":"M Contini","year":"2013","unstructured":"Contini M, Apostolo A, Cattadori G et al (2013) Multiparametric comparison of carvedilol, vs. nebivolol, vs. bisoprolol in moderate heart failure: the CARNEBI trial. Int J Cardiol 168(3):2134\u20132140. https:\/\/doi.org\/10.1016\/j.ijcard.2013.01.277","journal-title":"Int J Cardiol"},{"issue":"7","key":"10566_CR70","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/j.ejheart.2006.02.001","volume":"8","author":"P Agostoni","year":"2006","unstructured":"Agostoni P, Contini M, Magini A et al (2006) Carvedilol reduces exercise-induced hyperventilation: a benefit in normoxia and a problem with hypoxia. Eur J Heart Fail 8(7):729\u2013735. https:\/\/doi.org\/10.1016\/j.ejheart.2006.02.001","journal-title":"Eur J Heart Fail"},{"issue":"4","key":"10566_CR71","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/j.amjcard.2012.10.041","volume":"111","author":"RJ Mentz","year":"2013","unstructured":"Mentz RJ, Wojdyla D, Fiuzat M, Chiswell K, Fonarow GC, O\u2019Connor CM (2013) Association of beta-blocker use and selectivity with outcomes in patients with heart failure and chronic obstructive pulmonary disease (from OPTIMIZE-HF). Am J Cardiol 111(4):582\u2013587. https:\/\/doi.org\/10.1016\/j.amjcard.2012.10.041","journal-title":"Am J Cardiol"},{"key":"10566_CR72","doi-asserted-by":"publisher","first-page":"515","DOI":"10.2147\/COPD.S79942","volume":"10","author":"Y Kubota","year":"2015","unstructured":"Kubota Y, Asai K, Furuse E et al (2015) Impact of \u03b2-blocker selectivity on long-term outcomes in congestive heart failure patients with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 10:515\u2013523. https:\/\/doi.org\/10.2147\/COPD.S79942","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"1","key":"10566_CR73","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1136\/thoraxjnl-2015-207251","volume":"71","author":"SP Bhatt","year":"2016","unstructured":"Bhatt SP, Wells JM, Kinney GL et al (2016) \u0392-blockers are associated with a reduction in COPD exacerbations. Thorax 71(1):8\u201314. https:\/\/doi.org\/10.1136\/thoraxjnl-2015-207251","journal-title":"Thorax"},{"issue":"5","key":"10566_CR74","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000002427","volume":"95","author":"VYF Su","year":"2016","unstructured":"Su VYF, Chang YS, Hu YW et al (2016) Carvedilol, bisoprolol, and metoprolol use in patients with coexistent heart failure and chronic obstructive pulmonary disease. Medicine 95(5):e2427. https:\/\/doi.org\/10.1097\/MD.0000000000002427","journal-title":"Medicine"},{"issue":"1","key":"10566_CR75","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1186\/s12931-017-0609-7","volume":"18","author":"S Duffy","year":"2017","unstructured":"Duffy S, Marron R, Voelker H et al (2017) Effect of beta-blockers on exacerbation rate and lung function in chronic obstructive pulmonary disease (COPD). Respir Res 18(1):124. https:\/\/doi.org\/10.1186\/s12931-017-0609-7","journal-title":"Respir Res"},{"key":"10566_CR76","doi-asserted-by":"publisher","first-page":"2987","DOI":"10.2147\/COPD.S145913","volume":"12","author":"YL Huang","year":"2017","unstructured":"Huang YL, Lai CC, Wang YH et al (2017) Impact of selective and nonselective beta-blockers on the risk of severe exacerbations in patients with COPD. Int J Chron Obstruct Pulmon Dis 12:2987\u20132996. https:\/\/doi.org\/10.2147\/COPD.S145913","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"5","key":"10566_CR77","doi-asserted-by":"publisher","first-page":"3791","DOI":"10.1002\/ehf2.13489","volume":"8","author":"Y Kubota","year":"2021","unstructured":"Kubota Y, Tay WT, Teng THK et al (2021) Impact of beta-blocker use on the long-term outcomes of heart failure patients with chronic obstructive pulmonary disease. ESC Heart Fail 8(5):3791\u20133799. https:\/\/doi.org\/10.1002\/ehf2.13489","journal-title":"ESC Heart Fail"},{"issue":"6","key":"10566_CR78","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1177\/030006051204000602","volume":"40","author":"Y Ni","year":"2012","unstructured":"Ni Y, Shi G, Wan H (2012) Use of cardioselective \u03b2-blockers in patients with chronic obstructive pulmonary disease: a meta-analysis of randomized, placebo-controlled, blinded trials. J Int Med Res 40(6):2051\u20132065. https:\/\/doi.org\/10.1177\/030006051204000602","journal-title":"J Int Med Res"},{"issue":"11","key":"10566_CR79","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0113048","volume":"9","author":"Q Du","year":"2014","unstructured":"Du Q, Sun Y, Ding N, Lu L, Chen Y (2014) Beta-blockers reduced the risk of mortality and exacerbation in patients with COPD: a meta-analysis of observational studies. PLoS ONE 9(11):e113048. https:\/\/doi.org\/10.1371\/journal.pone.0113048","journal-title":"PLoS ONE"},{"issue":"1","key":"10566_CR80","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s12931-021-01661-8","volume":"22","author":"C Gulea","year":"2021","unstructured":"Gulea C, Zakeri R, Alderman V, Morgan A, Ross J, Quint JK (2021) Beta-blocker therapy in patients with COPD: a systematic literature review and meta-analysis with multiple treatment comparison. Respir Res 22(1):64. https:\/\/doi.org\/10.1186\/s12931-021-01661-8","journal-title":"Respir Res"},{"issue":"24","key":"10566_CR81","doi-asserted-by":"publisher","first-page":"2304","DOI":"10.1056\/NEJMoa1908142","volume":"381","author":"MT Dransfield","year":"2019","unstructured":"Dransfield MT, Voelker H, Bhatt SP et al (2019) Metoprolol for the prevention of acute exacerbations of COPD. N Engl J Med 381(24):2304\u20132314. https:\/\/doi.org\/10.1056\/NEJMoa1908142","journal-title":"N Engl J Med"},{"key":"10566_CR82","doi-asserted-by":"publisher","unstructured":"Beer BN, Benson L, Basile C et al (2025) Beta-blockers in patients with heart failure with reduced ejection fraction and concomitant chronic obstructive pulmonary disease: cardiovascular and respiratory outcomes. Eur J Heart Fail. https:\/\/doi.org\/10.1002\/ejhf.70046.Published online September 11, 2025","DOI":"10.1002\/ejhf.70046"},{"issue":"13","key":"10566_CR83","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1161\/CIRCULATIONAHA.124.072855","volume":"151","author":"C Basile","year":"2025","unstructured":"Basile C, Lindberg F, Benson L et al (2025) Withdrawal of guideline-directed medical therapy in patients with heart failure and improved ejection fraction. Circulation 151(13):931\u2013945. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.124.072855","journal-title":"Circulation"},{"issue":"21","key":"10566_CR84","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1016\/j.jacc.2011.02.020","volume":"57","author":"NM Hawkins","year":"2011","unstructured":"Hawkins NM, Petrie MC, MacDonald MR et al (2011) Heart failure and chronic obstructive pulmonary disease: the quandary of beta-blockers and beta-agonists. J Am Coll Cardiol 57(21):2127\u20132138. https:\/\/doi.org\/10.1016\/j.jacc.2011.02.020","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"10566_CR85","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.cardfail.2016.01.011","volume":"22","author":"M Fu","year":"2016","unstructured":"Fu M, Zhou J, Thunstr\u00f6m E et al (2016) Optimizing the management of heart failure with preserved ejection fraction in the elderly by targeting comorbidities (OPTIMIZE-HFPEF). J Card Fail 22(7):539\u2013544. https:\/\/doi.org\/10.1016\/j.cardfail.2016.01.011","journal-title":"J Card Fail"},{"issue":"1","key":"10566_CR86","doi-asserted-by":"publisher","first-page":"e7","DOI":"10.1016\/S2213-2600(24)00413-2","volume":"13","author":"P Venkatesan","year":"2025","unstructured":"Venkatesan P (2025) GOLD COPD report: 2025 update. Lancet Respir Med 13(1):e7\u2013e8. https:\/\/doi.org\/10.1016\/S2213-2600(24)00413-2","journal-title":"Lancet Respir Med"},{"issue":"1","key":"10566_CR87","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1097\/00005344-200207000-00017","volume":"40","author":"TMH Ng","year":"2002","unstructured":"Ng TMH, Munger MA, Lombardi WL et al (2002) Chronically inhaled salmeterol improves pulmonary function in heart failure. J Cardiovasc Pharmacol 40(1):140\u2013145. https:\/\/doi.org\/10.1097\/00005344-200207000-00017","journal-title":"J Cardiovasc Pharmacol"},{"issue":"3","key":"10566_CR88","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1161\/01.res.59.3.297","volume":"59","author":"MR Bristow","year":"1986","unstructured":"Bristow MR, Ginsburg R, Umans V et al (1986) Beta 1- and beta 2-adrenergic-receptor subpopulations in nonfailing and failing human ventricular myocardium: coupling of both receptor subtypes to muscle contraction and selective beta 1-receptor down-regulation in heart failure. Circ Res 59(3):297\u2013309. https:\/\/doi.org\/10.1161\/01.res.59.3.297","journal-title":"Circ Res"},{"issue":"5","key":"10566_CR89","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/S2213-2600(18)30054-7","volume":"6","author":"JM Hohlfeld","year":"2018","unstructured":"Hohlfeld JM, Vogel-Claussen J, Biller H et al (2018) Effect of lung deflation with indacaterol plus glycopyrronium on ventricular filling in patients with hyperinflation and COPD (CLAIM): a double-blind, randomised, crossover, placebo-controlled, single-centre trial. Lancet Respir Med 6(5):368\u2013378. https:\/\/doi.org\/10.1016\/S2213-2600(18)30054-7","journal-title":"Lancet Respir Med"},{"issue":"8","key":"10566_CR90","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1136\/thx.2010.136077","volume":"65","author":"PMA Calverley","year":"2010","unstructured":"Calverley PMA, Anderson JA, Celli B et al (2010) Cardiovascular events in patients with COPD: TORCH study results. Thorax 65(8):719\u2013725. https:\/\/doi.org\/10.1136\/thx.2010.136077","journal-title":"Thorax"},{"issue":"10030","key":"10566_CR91","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1016\/S0140-6736(16)30069-1","volume":"387","author":"J Vestbo","year":"2016","unstructured":"Vestbo J, Anderson JA, Brook RD et al (2016) Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial. Lancet 387(10030):1817\u20131826. https:\/\/doi.org\/10.1016\/S0140-6736(16)30069-1","journal-title":"Lancet"},{"issue":"13","key":"10566_CR92","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1001\/jamainternmed.2013.1016","volume":"173","author":"A Gershon","year":"2013","unstructured":"Gershon A, Croxford R, Calzavara A et al (2013) Cardiovascular safety of inhaled long-acting bronchodilators in individuals with chronic obstructive pulmonary disease. JAMA Intern Med 173(13):1175\u20131185. https:\/\/doi.org\/10.1001\/jamainternmed.2013.1016","journal-title":"JAMA Intern Med"},{"key":"10566_CR93","doi-asserted-by":"publisher","first-page":"205031211667133","DOI":"10.1177\/2050312116671337","volume":"4","author":"A Aljaafareh","year":"2016","unstructured":"Aljaafareh A, Valle JR, Lin YL, Kuo YF, Sharma G (2016) Risk of cardiovascular events after initiation of long-acting bronchodilators in patients with chronic obstructive lung disease: a population-based study. SAGE Open Med 4:2050312116671337. https:\/\/doi.org\/10.1177\/2050312116671337","journal-title":"SAGE Open Med"},{"key":"10566_CR94","doi-asserted-by":"publisher","unstructured":"Suissa S, Dell\u2019Aniello S, Ernst P (2017) Concurrent use of long-acting bronchodilators in COPD and the risk of adverse cardiovascular events. Eur Respir J 49(5). https:\/\/doi.org\/10.1183\/13993003.02245-2016","DOI":"10.1183\/13993003.02245-2016"},{"issue":"11","key":"10566_CR95","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1177\/1060028017719716","volume":"51","author":"JC Samp","year":"2017","unstructured":"Samp JC, Joo MJ, Schumock GT, Calip GS, Pickard AS, Lee TA (2017) Risk of cardiovascular and cerebrovascular events in COPD patients treated with long-acting \u03b22-agonist combined with a long-acting muscarinic or inhaled corticosteroid. Ann Pharmacother 51(11):945\u2013953. https:\/\/doi.org\/10.1177\/1060028017719716","journal-title":"Ann Pharmacother"},{"issue":"2","key":"10566_CR96","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1001\/jamainternmed.2017.7720","volume":"178","author":"MT Wang","year":"2018","unstructured":"Wang MT, Liou JT, Lin CW et al (2018) Association of cardiovascular risk with inhaled long-acting bronchodilators in patients with chronic obstructive pulmonary disease: a nested case-control study. JAMA Intern Med 178(2):229\u2013238. https:\/\/doi.org\/10.1001\/jamainternmed.2017.7720","journal-title":"JAMA Intern Med"},{"key":"10566_CR97","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.2147\/COPD.S358927","volume":"17","author":"JE Amegadzie","year":"2022","unstructured":"Amegadzie JE, Gamble JM, Farrell J, Gao Z (2022) Association between inhaled \u03b22-agonists initiation and risk of major adverse cardiovascular events: a population-based nested case-control study. Int J Chron Obstruct Pulmon Dis 17:1205\u20131217. https:\/\/doi.org\/10.2147\/COPD.S358927","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"10566_CR98","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.hrtlng.2024.12.010","volume":"70","author":"N Lev-Ari","year":"2025","unstructured":"Lev-Ari N, Oberman B, Kushnir S, Yosef N, Shlomi D (2025) The cardiovascular effects of long-acting bronchodilators inhalers and inhaled corticosteroids purchases among asthma and COPD patients. Heart & Lung: The Journal of Cardiopulmonary and Acute Care 70:250\u2013257. https:\/\/doi.org\/10.1016\/j.hrtlng.2024.12.010","journal-title":"Heart & Lung: The Journal of Cardiopulmonary and Acute Care"},{"key":"10566_CR99","doi-asserted-by":"publisher","first-page":"799","DOI":"10.2147\/COPD.S198288","volume":"14","author":"C Li","year":"2019","unstructured":"Li C, Cheng W, Guo J, Guan W (2019) Relationship of inhaled long-acting bronchodilators with cardiovascular outcomes among patients with stable COPD: a meta-analysis and systematic review of 43 randomized trials. COPD 14:799\u2013808. https:\/\/doi.org\/10.2147\/COPD.S198288","journal-title":"COPD"},{"issue":"6","key":"10566_CR100","doi-asserted-by":"publisher","first-page":"1964","DOI":"10.1378\/chest.123.6.1964","volume":"123","author":"DH Au","year":"2003","unstructured":"Au DH, Udris EM, Fan VS, Curtis JR, McDonell MB, Fihn SD (2003) Risk of mortality and heart failure exacerbations associated with inhaled \u03b2-adrenoceptor agonists among patients with known left ventricular systolic dysfunctiona. Chest 123(6):1964\u20131969. https:\/\/doi.org\/10.1378\/chest.123.6.1964","journal-title":"Chest"},{"issue":"5","key":"10566_CR101","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1016\/j.ahj.2004.03.048","volume":"148","author":"DH Au","year":"2004","unstructured":"Au DH, Udris EM, Curtis JR, McDonell MB, Fihn SD, ACQUIP Investigators (2004) Association between chronic heart failure and inhaled beta-2-adrenoceptor agonists. Am Heart J 148(5):915\u2013920. https:\/\/doi.org\/10.1016\/j.ahj.2004.03.048","journal-title":"Am Heart J"},{"issue":"8","key":"10566_CR102","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1093\/eurjhf\/hfr063","volume":"13","author":"M Bermingham","year":"2011","unstructured":"Bermingham M, O\u2019Callaghan E, Dawkins I et al (2011) Are beta2-agonists responsible for increased mortality in heart failure? Eur J Heart Fail 13(8):885\u2013891. https:\/\/doi.org\/10.1093\/eurjhf\/hfr063","journal-title":"Eur J Heart Fail"},{"key":"10566_CR103","doi-asserted-by":"publisher","DOI":"10.1136\/thorax-2024-222113","author":"AE Ioannides","year":"2025","unstructured":"Ioannides AE, Kallis C, Whittaker HR, Quint JK (2025) Inhaled corticosteroids and major cardiovascular events in people with chronic obstructive pulmonary disease. Thorax. https:\/\/doi.org\/10.1136\/thorax-2024-222113","journal-title":"Thorax"},{"issue":"8","key":"10566_CR104","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2018.5489","volume":"1","author":"CA Lawson","year":"2018","unstructured":"Lawson CA, Mamas MA, Jones PW et al (2018) Association of medication intensity and stages of airflow limitation with the risk of hospitalization or death in patients with heart failure and chronic obstructive pulmonary disease. JAMA Netw Open 1(8):e185489. https:\/\/doi.org\/10.1001\/jamanetworkopen.2018.5489","journal-title":"JAMA Netw Open"},{"issue":"9","key":"10566_CR105","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1093\/cvr\/20.9.637","volume":"20","author":"S Golf","year":"1986","unstructured":"Golf S, Hansson V (1986) Effects of beta blocking agents on the density of beta adrenoceptors and adenylate cyclase response in human myocardium: intrinsic sympathomimetic activity favours receptor upregulation. Cardiovasc Res 20(9):637\u2013644. https:\/\/doi.org\/10.1093\/cvr\/20.9.637","journal-title":"Cardiovasc Res"}],"container-title":["Heart Failure Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-025-10566-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10741-025-10566-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-025-10566-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T02:25:43Z","timestamp":1768443943000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10741-025-10566-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,7]]},"references-count":105,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["10566"],"URL":"https:\/\/doi.org\/10.1007\/s10741-025-10566-3","relation":{},"ISSN":["1573-7322"],"issn-type":[{"value":"1573-7322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,7]]},"assertion":[{"value":"30 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}